

AMENDMENT TO THE CLAIMS

Please amend the claims as follows:

1-38. (Cancelled)

39. (Currently Amended) A method for developing a therapeutic procedure in a model animal system comprising the steps of:

a) infecting a *Tupaia belangeri* with ~~a human viral pathogen, wherein said pathogen is HIV or HBV;~~

b) carrying out a potential therapeutic procedure in said infected *Tupaia belangeri*; and

c) evaluating the effect of said potential therapeutic procedure on a disease manifestation[[s]] caused by said human viral pathogen in said infected animal, wherein said disease manifestation is hepatic histological evidence of fibrosis, bile duct proliferation, lymphocytes, ground glass hepatocytes or a combination thereof.

40-42. (Cancelled)

43. (Previously Presented) The method of claim 39 wherein said potential therapeutic procedure comprises oral tolerization.

44-48. (Cancelled)

49. (Currently Amended) A method for developing a therapeutic procedure which alleviates a clinical manifestation of a disease caused by ~~a human viral pathogen, wherein said pathogen is HBV, the method~~ comprising the steps of:

a) infecting a *Tupaia belangeri* with HBV;

b) carrying out a potential therapeutic procedure in said infected *Tupaia belangeri*, wherein said potential therapeutic procedure is oral tolerization; and

ENZ-57(CIP)(C)

Jennifer June Brown et al.

Serial No. 10/042,711

Filed: December 12, 2001

Page 3 (Reply and Amendment to November 2, 2010 Office Action)

c) evaluating the effect of said therapeutic procedure on the clinical manifestation caused by said human viral pathogen.

50. (Previously Presented) The method of claim 49 wherein said clinical manifestation is hepatic histological evidence of fibrosis, bile duct proliferation, lymphocytes, ground glass hepatocytes or a combination thereof ~~potential therapeutic procedure comprises oral tolerization.~~

51-78. (Cancelled)